150586-58-6

Fipamezole (MPV 1730; JP-1730) is a potent and orally active α2-adrenergic receptor antagonist with Ki values of 9.2 nM, 17 nM, and 55 nM for human α2A, α2B, and α2C, receptors, respectively. Fipamezole is an anti-dyskinetic agent, and can be used for the study of Parkinson's disease[1].

human α2A-adrenoceptor: 9.2 nM (Ki); human α2B-adrenoceptor: 17 nM (Ki); human α2C-adrenoceptor: 55 nM (Ki)

[1] Juha-Matti Savola, et al. Fipamezole (JP-1730) is a potent alpha2 adrenergic receptor antagonist that reduces levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease. Mov Disord. 2003 Aug;18(8):872-83. DOI:10.1002/mds.10464